Real-world Evidence from a Narrow Therapeutic Index Product (Levothyroxine) Reflects the Therapeutic Equivalence of Generic Drug Products

It appears that some prescribers are not aware that FDA bioequivalence standards ensure that generic products do not differ in safety, efficacy, or quality (including potency) from regulatory standards that govern brand-name products.

Source: FDA Center for Drug Evaluation and Research - What's New - October 2, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news